Clinical trialObsCompleted
Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer
Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer: a Real Life Scenario
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- 1 January 2019
- Expected end
- 28 February 2024
- Enrollment
- 317 participants
- Sites
- 1
- Primary outcomes
- Rate of patients who fail to receive adjuvant therapy and reasons for that; Rate of patients who fail to complete adjuvant therapy and reasons for that
- Sponsor
- Other
- Results posted
- No
- Last update
- 7 May 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study aims to evaluate the rate of patients submitted to pancreatic resection for pancreatic cancer, who fail to access to adjuvant therapy or do not complete adjuvant therapy. The purpose is to give an overview concerning the most frequent conditions and/or reasons associated with failure or omission of adjuvant therapy.
Detailed description public domain (ClinicalTrials.gov)
This prospective observational study will evaluate all patients submitted to pancreatic resection for pancreatic cancer. The rate of omission to adjuvant therapy and rate of failure of completion of adjuvant therapy will be evaluated as primary outcomes. As secondary outcomes, survival analyses will be performed to investigate whether these factors influence prognosis, that will be evaluated through a disease free survival analysis at 18-months. Epidemiological and perioperative data will be analyzed to identify conditions associated with the primary outcomes.